Nicos Peciardis | Nurphoto | Getty images
Robert f. Kennedy Junior revives government Panel of vaccine advisors Recommended to use on Thursday MerkInfants were shot to protect from respiratory synchronous viruses, a temporary recurrence for public health officials and companies Connected About the vaccination policy of Health and Human Services Secretary.
The group, called the vaccination practices, or the Advisory Committee on ACIP, also unanimously voted, in which Merc’s shot was included in the list of childhood vaccinations recommended by the government that receive comprehensive insurance coverage.
Injectable antibodies, votes in favor of Enflonia, take a sigh of relief for drug manufacturers and medical community after Kennedy earlier this month Put the panel And tapped replacement, some of which are famous vaccine critics.
The signoff will allow the company to launch shots before the RSV season that usually falls around the fall and winter and lives through spring. Enfallonia recommended for infants during your first RSV season will compete with a head-to-head with a rival shot Soxy And Astrazheneka Is called beyfortus.
Both preventive are monoclonal antibodies, which provide antibodies directly to the bloodstream to provide immediate protection. But each targets a separate part of each virus, making them difficult to compare directly.
The RSV causes thousands of deaths between old Americans and hundreds of deaths between infants each year, and complications from the virus are the main reasons for hospitalization among newborns. In A For late phase testing on Enflonia, the shot declined more than 84% in the hospital -related hospital and a decrease in the hospital due to less respiratory infection than a placebo among infants through five months.
Two of the vaccine critics on the panel, Levi and Vicky Pabsworth voted against the recommendation of Merc’s shot and questioned its safety during the meeting.
But some other members underlined the safety of Merc’s shot, which won Approval Earlier this month from Food and Drug Administration.
“They are really remarkable products. They are safe and they are effective, and I do not think there is a need to present any other data,” Dr. Dr. Dr. of Pediatrics at Gesel School of Medicine in Dartmouth. Kodi Meesner said.
ACIP “Work Group has spent a huge amount of time, the FDA has made huge amounts of efforts in view of security and efficacy, and this is not just an issue here,” the Meesner said, who has played advisory roles in CDC and FDA.
Other experts in the meeting, who are not members of the committee, agreed.
President of the American College of Physicians, Dr. Jason Goldman said, “This is a tremendous advance for medical science, and I urge the committee to approve and pass this resolution so that we can continue to protect our children and keep them healthy.”
Levi said he voted against the shot as he believes that it is “not ready to be administered for all healthy infants. He said,” I think we should take a more precautionary approach for this. ,
The vote especially recommends a dose of the merc shot for infants 8 months or younger or was born during its first RSV season.
